Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings

✍ Scribed by Abdel-Fatah, T. M. A.; Perry, C.; Dickinson, P.; Ball, G.; Moseley, P.; Madhusudan, S.; Ellis, I. O.; Chan, S. Y. T.

• Book ID: 121343848
• Publisher: Oxford University Press
• Year: 2013
• Tongue: English
• Weight: 680 KB
• Volume: 24
• Category: Article
• ISSN: 0923-7534
• DOI: 10.1093/annonc/mdt277